MedTrace Logo

Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine

NCT01131468 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-05-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether N-acetylcysteine is effective in the prevention of hearing loss in both ears due to aminoglycoside and/or vancomycine induced ototoxicity in peritoneal dialysis patients.

Conditions

  • Drug-induced Ototoxicity in Peritoneal Dialysis Patients

Interventions

DRUG

N-acetylcysteine

N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone

Sponsors & Collaborators

  • TC Erciyes University

    lead OTHER

Principal Investigators

  • Bulent Tokgoz, MD · Erciyes University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-04-30
Completion
2010-05-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01131468 on ClinicalTrials.gov